Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced HER2 Negative Breast Carcinoma|HRD+Breast Cancer
Interventions: DRUG: fluzoparib+chidamide|DRUG: fluzoparib+camrelizumab
Sponsor: Tianjin Medical University Cancer Institute and Hospital